TNFRSF17 and Miyoshi myopathy: This biologic was developed by a giant in the pharma industry (Janssen Biotech) that has been granted authorization for many biologics for the treatment of MM in recent years, including its own bispecific mAb which, like the newly approved elranatamab [2,3] targets CD3 and BCMA.